|
Clinical characteristics
|
|
Age
|
55.7 ± 12.4
|
59.0 ± 9.6
|
55.9 ± 10.6
|
0.39
|
|
Post-menopausal
|
9 (60%)
|
22 (81%)
|
50 (69%)
|
0.40
|
|
Hypertension
|
4 (27%)
|
10 (37%)
|
25 (35%)
|
0.79
|
|
Diabetes
|
1 (7%)
|
2 (7%)
|
12 (17%)
|
0.42
|
|
Hyperlipidemia
|
1 (7%)
|
3 (11%)
|
9 (13%)
|
1.00
|
|
Cigarette smoking (current)
|
2 (13%)
|
8 (30%)
|
10 (14%)
|
0.19
|
|
Congestive heart failure
|
0
|
0
|
1 (1%)
|
1.00
|
|
Valve disease
|
0
|
0
|
1 (1%)
|
1.00
|
|
Arrhythmia
|
0
|
0
|
2 (3%)
|
1.00
|
|
Coronary artery disease
|
0
|
1 (4%)
|
1 (1%)
|
0.60
|
|
Stroke
|
0
|
0
|
0
|
N/A
|
|
HF symptoms with LVEF decline
|
8 (53%)
|
4(15%)
|
15 (21%)
|
0.01
|
|
Cancer characteristics
| |
|
Left-sided cancer
|
9 (60%)
|
14 (52%)
|
39 (54%)
|
0.10
|
|
Lymph node involvement
|
7 (47%)
|
14 (52%)
|
37 (51%)
|
0.94
|
|
Treatment characteristics
| |
|
Mastectomy
|
11 (73%)
|
24 (89%)
|
61 (85%)
|
0.42
|
|
Radiation
|
13 (87%)
|
21 (78%)
|
53 (74%)
|
0.55
|
|
Radiation dose (Gy)
|
55 (42.5,90)
|
80 (40,98.4)
|
53.75 (0,87.25)
|
0.45
|
|
Anthracycline
|
15 (100%)
|
25 (93%)
|
61 (85%)
|
0.23
|
|
Cumulative dose (mg/m2)
|
240 (240,240)
|
240 (150,240)
|
240 (150,240)
|
0.04
|
|
Trastuzumab cycles received
|
7 (4,11)
|
14 (10,17)
|
16 (10,17)
|
0.002
|
|
Trastuzumab interruption
|
15 (100%)
|
27 (100%)
|
67 (93%)
|
0.10
|
|
Trastuzumab re-started
|
6 (40%)
|
16 (59%)
|
43 (60%)
|
0.36
|
|
Completed planned trastuzumab
|
1 (7%)
|
10 (37%)
|
35 (49%)
|
0.01
|
|
Other management
|
|
Cardiology referral
|
14 (93%)
|
21 (78%)
|
40 (56%)
|
0.006
|
|
Beta blocker
|
15 (100%)
|
14 (52%)
|
28 (39%)
|
< 0.0001
|
|
ACE inhibitor
|
15 (100%)
|
18 (67%)
|
38 (53%)
|
0.002
|
|
Loop diuretic
|
9 (60%)
|
7 (26%)
|
8 (11%)
|
0.0001
|
|
Mineralocorticoid receptor antagonist
|
9 (60%)
|
1 (4%)
|
1 (1%)
|
< 0.0001
|
|
Outcomes
|
|
Breast cancer recurrence
|
3 (20%)
|
5 (19%)
|
12 (17%)
|
0.88
|
|
All cause mortality
|
1 (7%)
|
4 (15%)
|
6 (8%)
|
0.64
|
